JoeBelanoff

Walk into most biotech boardrooms and you'll find someone explaining why cortisol matters. Joe Belanoff spent the last three decades proving it. As co-founder and CEO of Corcept Therapeutics, he has quietly built one of biotechnology's most focused research enterprises - a company organized around a single biological insight that excess cortisol does far more damage than medicine has historically credited it for.

In March 2026, the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer. It is the first selective glucocorticoid receptor antagonist ever cleared by the agency. The clinical data behind it - a 35% reduction in risk of death compared to nab-paclitaxel alone - is the kind of number that changes treatment paradigms. Belanoff has been working toward that number for the better part of three decades.

The path here was neither straight nor fast. Belanoff trained as a psychiatrist at Stanford and Columbia, did residency work examining how cortisol disturbance drives psychiatric and metabolic disease, and then - in one of those rare departures from comfortable academic trajectories - chose to commercialize the science rather than continue publishing it. "I never thought I would return to doing business again once I had gotten into medical school," he has said. But he did, leveraging a pre-medicine Wall Street background to raise venture capital and co-found Corcept in May 1998 with Stanford psychiatry chair Alan Schatzberg.

That transparency commitment is not window dressing. Corcept requires all researchers funded through its collaborative network to publish results regardless of outcome - a stipulation that sits outside pharmaceutical industry norms and costs the company nothing except the occasional published failure. Belanoff's logic is straightforward: negative data, widely shared, saves the field years of duplicated effort. It also tends to attract the kind of researchers who care about the science rather than the headline.

The model has produced results that speak for themselves. Corcept's first drug, Korlym (mifepristone), received FDA approval in 2012 for Cushing's syndrome complicated by type 2 diabetes - the first treatment specifically indicated for that combination. Fourteen years later, Lifyorli arrived as the company's second approved drug, targeting a disease - platinum-resistant ovarian cancer - that had very few good options. These are not adjacent achievements. They are two points in a research architecture that spans oncology, metabolism, neurology, and psychiatry, all connected by the biology of cortisol excess.

The conventional path from financial services to medicine to biotechnology founder is uncommon enough to be worth examining. Belanoff started in finance - the kind of business-side grounding that pharmaceutical academics rarely bring to their work. Then came medical school at Columbia's College of Physicians and Surgeons, residency at Stanford, and a faculty position in the psychiatry department that lasted decades and technically still continues as an adjunct role.

The pivot point was the intellectual property. Belanoff and his research partner Alan Schatzberg had developed significant IP around a class of medications targeting cortisol's receptor - compounds with potential applications far beyond what any existing drug covered. The choice was a familiar one in academic medicine: license the patents to an established pharmaceutical company and move on, or build a company around them.

Belanoff chose the second option. His Wall Street background, dormant for years, turned out to matter. He understood term sheets, capitalization tables, and how venture investors think about risk - knowledge that is genuinely unusual in a physician-scientist founding team. Corcept launched in May 1998. By January 1999, Belanoff was CEO. He has remained CEO ever since.

The collaborative research model Corcept built is part of what makes the company structurally different from most in its peer group. Rather than internalizing all discovery work, Belanoff built a global network of academic investigators working on cortisol-related questions, funded through Corcept but required to publish their findings. This model keeps Corcept connected to the frontiers of basic science without having to own all of it - and the transparency requirement means the company's reputation in academic circles remains intact even when trials fail.

More than 30 ongoing clinical studies now run within this network. The pipeline covers conditions ranging from Cushing's syndrome variants to ovarian cancer to metabolic disorders - all anchored in the same glucocorticoid receptor biology that started the company in 1998.